190 related articles for article (PubMed ID: 26636329)
1. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
[TBL] [Abstract][Full Text] [Related]
2. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
[No Abstract] [Full Text] [Related]
4. Meningeal marginal zone B-cell lymphoma: The meningioma trap.
Villeneuve A; Rubin F; Bonfils P
Eur Ann Otorhinolaryngol Head Neck Dis; 2018 Apr; 135(2):131-132. PubMed ID: 29331570
[TBL] [Abstract][Full Text] [Related]
5. Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma.
Yamasaki M; Funaishi K; Muta T; Matsumoto N; Taniwaki M; Hattori N
QJM; 2019 Oct; 112(10):807-808. PubMed ID: 30895318
[No Abstract] [Full Text] [Related]
6. Mucosa-associated lymphoid tissue lymphoma with unusual
Zhang NS; Shi F; Kong L; Zhu H
World J Gastroenterol; 2017 Jan; 23(3):551-559. PubMed ID: 28210093
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
8. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
9. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
Cencini E; Fabbri A; Schiattone L; Bocchia M
Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
[No Abstract] [Full Text] [Related]
13. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
14. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
15. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
17. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
18. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
19. Minimal change disease associated with MALT lymphoma.
Kasmani R; Marina VP; Abidi S; Johar B; Malhotra D
Int Urol Nephrol; 2012 Dec; 44(6):1911-3. PubMed ID: 21594766
[TBL] [Abstract][Full Text] [Related]
20. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
